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 2 
Abstract 13 
The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, 14 
since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. 15 
The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. 16 
Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs 17 
nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we 18 
developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two 19 
candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS 20 
vaccines were produced with or without the leader sequence of the human tissue plasminogen activator 21 
gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter 22 
driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime 23 
only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than 24 
ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune 25 
responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA 26 
MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two 27 
doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody 28 
levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly 29 
higher magnitudes.  In conclusion, our study showed that MERS-CoV vaccine candidates could be 30 
optimised by utilising different viral vectors, various genetic designs of the vectors, or different regimens 31 
to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels 32 
and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials. 33
 3 
Introduction 34 
Middle East respiratory syndrome (MERS) is caused by a novel betacoronavirus (MERS-CoV) that was 35 
isolated in late 2012 in Saudi Arabia (1). The syndrome (MERS) is described as a viral infection that 36 
causes fever, cough, and/or shortness of breath and to a lesser extent gastrointestinal symptoms such 37 
as diarrhea (2). Severe disease from MERS-CoV infection can cause respiratory failure and organ failure, 38 
and cases can be fatal, especially in patients with co-morbidities such as diabetes and cardiac 39 
complications. However, the infection can be asymptomatic or mild in many cases (3-7). MERS-CoV has 40 
spread to 27 countries and infected more than 1900 humans with a mortality rate of 40% (2). 41 
Dromedary camels, especially juveniles, contract the infection and shed the virus, without notable 42 
symptoms of disease; this is now known to have been occurring since the early 1980s (8-13). The 43 
mechanism of camel to human transmission is still not clear, but several primary cases have been 44 
associated with camel contact, which is considered an important risk factor (14-16). Therefore, camels 45 
are being considered an intermediate host and one of the sources of MERS-CoV infection (8-13). Other 46 
livestock animals such as sheep, goats, cows, chicken, and horses have proved seronegative in many 47 
studies (17-20). Further, these animals did not productively contract MERS-CoV when they were 48 
inoculated experimentally (21, 22). Therefore, to date, dromedary camels are the only confirmed animal 49 
reservoir. There is currently no approved vaccine against MZ^ ?Žsfor camels or humans despite active 50 
vaccine research and development. A number of vaccine candidates have been developed using various 51 
platforms and regimens and have been tested in several animal models (23). Viral vectors are potent 52 
platform technologies that have been utilised to develop vaccines against malaria, tuberculosis, 53 
influenza, HIV, HCV, Ebola, and many viral pathogens. These vectors include adenoviruses, poxviruses, 54 
yellow fever viruses, and alphaviruses (24, 25), and they are preferred for their ability to induce cellular 55 
immune responses in addition to humoral immunity. Here, we report development of MERS-CoV 56 
vaccine candidates that are based on two different viral vectors: Chimpanzee Adenovirus, Oxford 57 
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University #1 (ChAdOx1) (26) and Modified Vaccinia virus Ankara (MVA) (27, 28). Each viral vector was 58 
developed by generating two alternative versions, resulting in four vaccine candidates that all encode 59 
the same complete MERS-CoV spike gene (S). The two ChAdOx1 based vaccines were produced with or 60 
without the signal peptide of the human tissue plasminogen activator gene (tPA) at the N terminus. 61 
Previous studies have shown that encoding tPA upstream of recombinant antigens enhanced 62 
immunogencity, although results differed depending on the antigens employed. The tPA encoded 63 
upstream of influenza A virus nucleoprotein, in a DNA vector, enhanced both cellular and humoral 64 
immune responses in mice (29, 30), whereas the same leader sequence resulted in increased humoral 65 
sequences but decreased cellular responses to HIV Gag (30). The two MVA based vaccines were 66 
produced with either the mH5 or F11 poxviral promoter driving antigen expression, both including the 67 
tPA sequence at the N terminus of MERS-CoV Spike protein. Previously, we reported the ability of the 68 
strong early F11 promoter to enhance cellular immunogenicity of vaccine antigen candidates for malaria 69 
and influenza, as compared to utilising p7.5 or mH5 early/late promoters which resulted in a lower level 70 
of gene expression immediately after virus infection of target cells, but higher levels at a later stage (31). 71 
Here, we continue to assess the F11 promoter in enhancing cellular immunogenicity, and to investigate 72 
its ability to impact on humoral immune responses. The four vaccine candidates were evaluated in a 73 
number of different regimens in mouse models that showed a single dose of ChAdOx1 MERS inducing 74 
higher cellular and humoral immunogenicity than a single dose of MVA MERS, or equivalent to two 75 
doses of MVA MERS. ChAdOx1 based vaccines have been tested in different animal models, including 76 
camels (32), and in human clinical trials and proved safe and immunogenic (33). Therefore, based on our 77 
data, ChAdOx1 MERS can be readily developed for use as a MERS vaccine in humans. Furthermore, 78 
utilising ChAdOx1 MERS for camel vaccination can serve the one-health approach whereby blocking 79 
MERS-CoV transmission in camels is expected to prevent human infections.  80 
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Materials and methods 81 
Transgene and shuttle vector cloning 82 
The spike (S) gene of MERS-CoV camel isolate (Genbank accession number: KJ650098.1) was synthesised 83 
by GeneArt Gene Synthesis (Thermo Fisher Scientific). The S transgene was then cloned into four shuttle 84 
plasmid vectors following In-Fusion cloning (Clontech). Two plasmids contained the S transgene within 85 
the E1 homologous region of ChAdOx1, driven by the human cytomegalovirus major immediate early 86 
promoter (IE CMV) that includes intron A. One of the ChAdOx1 shuttle plasmids was designed to include 87 
the tPA signal sequence upstream of the transgene sequence while the second plasmid did not contain 88 
the tPA. The ChAdOx1 shuttle plasmids contained the S transgene within Gateway® recombination 89 
cassettes. To construct MVA MERS, one of the shuttle plasmids for MVA was designed to have the 90 
upstream and downstream (flanks) of the F11L ORF as homologous sequence arms. Inserting the S 91 
transgene within these arms enabled the utilisation of the endogenous F11 promoter, which is part of 92 
the right homologous arm, while deleting the native F11L ORF. This resulted in the shuttle vector for 93 
generation of F11-MVA MERS (F11 shuttle vector). The mH5 promoter sequence was subcloned 94 
upstream of the S transgene; and this mH5-S transgene was then subcloned into the F11 shuttle vector. 95 
This resulted in the shuttle vector for generation of mH5-MVA MERS (F11/mH5 shuttle vector). mH5-96 
MVA MERS contained the mH5 promoter at the F11L locus, however, the endogenous F11 promoter is 97 
intact and located upstream of the mH5 promoter. The endogenous F11 promoter could not be replaced 98 
with the mH5 since it is part of the essential upstream ORF.  99 
Immunostaining for Transgene Expression 100 
The ChAdOx1 shuttle plasmid, described above, was used to validate the expression of MERS-CoV spike 101 
protein in vitro. An African green monkey kidney cell line (Vero cells) was seeded into 6-well plate to 102 
80% confluence. Then the plasmid DNA was transfected into Vero cells using Lipofectamine® 2000 103 
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(Thermo Fisher Scientific) following ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶ ? dǁĞŶƚǇ ĨŽƵƌ ŚŽƵƌƐ ĂĨƚĞƌ ƚƌĂŶƐĨĞĐƚŝŽŶ ?104 
cells were fixed, permeabilised, and immunostained using a rabbit polyclonal anti-MERS-CoV spike 105 
antibody, following standard protocols. DAPI stain was used to label nuclei. 106 
  Construction of recombinant ChAdOx1 and MVA encoding MERS-CoV S antigens 107 
The ChAdOx1 MERS vaccines were prepared by Gateway® recombination between the ChAdOx1 108 
destination DNA BAC vector (described in (26)) and entry plasmids containing the coding sequence for 109 
MERS-CoV spike gene (ChAdOx1 shuttle vectors explained above), according to standard protocols. 110 
ChAdOx1 MERS genomes were then derived in HEK293A cell lines (Invitrogen, Cat. R705-07), the 111 
resultant viruses were purified by CsCl gradient ultracentrifugation as previously described (34). The 112 
titres were determined on HEK293A cells using anti-hexon immunostaining assay based on the 113 
YƵŝĐŬdŝƚĞƌ ? ĚĞŶŽǀŝƌƵƐ dŝƚĞƌ /ŵŵƵŶŽĂƐƐĂǇ Ŭŝƚ  ?Ğůů ŝŽůĂďƐ /ŶĐ ?. For MVA MERS vaccines chicken 114 
embryo fibroblast cells (CEFs) were infected with MVA parental virus that encodes dsRed marker instead 115 
of the native F11L ORF and transfected with MVA shuttle plasmids containing MERS-CoV spike gene 116 
(explained above) to allow recombination with the MVA genome and deletion of dsRed marker whilst 117 
keeping the F11 promoter sequence. Recombinant MVA expressing MERS-CoV S protein was purified by 118 
plaque-picking and fluorescent selection using the sorting function of CyCLONE robotic module of a 119 
MoFlo Flow cytometer (Dako Cytomation, Denmark) as previously described (31). F11-MVA MERS and 120 
mH5-MVA MERS were confirmed to lack the native F11L ORF (and the dsRed marker), and contain 121 
MERS-CoV S by PCR (identity and purity PCR screening). The sequence of the S transgene amplified from 122 
these vaccines was confirmed. The recombinant viruses (vaccines) were amplified in 1500 cm
2
 123 
monolayers of CEFs cells, partially purified over sucrose cushions and titrated in CEFs cells according to 124 
standard practice, and purity and identity were again verified by PCR.  125 
Mouse!immunogenicity 126 
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Female BALB/c mice (Harlan, UK) aged 6 to 8 weeks were immunised intramuscularly (i.m.) in the upper 127 
leg (total volume 50 µL) with a total of 10
8 
IU of ChAdOx1 MERS with or without tPA or with a total of 128 
10
6
 pfu of either F11-MVA MERS or mH5-MVA MERS. For induction of short-term anaesthesia, animals 129 
were anaesthetised using vaporised IsoFloH. In prime only regimens, mice were vaccinated with 130 
ChAdOx1 with blood samples taken at 14 days post immunisation (d.p.i) or 28 d.p.i. for serum isolation; 131 
and spleens were collected at 28 d.p.i. In heterologous prime-boost regimens, mice were vaccinated 132 
with ChAdOx1 MERS and boosted with MVA MERS at 28 d.p.i; mice were bled at 28 d.p.i. (post-prime) or 133 
42 d.p.i (14 days post-boost) for serum isolation, and spleens were collected at 42 d.p.i. In homologous 134 
regimens, mice were vaccinated with MVA MERS and boosted with MVA MERS at 21 d.p.i; mice were 135 
bled on 21 d.p.i. (post-prime) or 42 d.p.i (post-boost) for serum isolation and spleens were collected at 136 
42 d.p.i.  137 
ELISpot, ICS, and flow cytometry 138 
Splenocytes were harvested for analysis by IFN-ɶ ELISpot or intracellular cytokine staining (ICS) and flow 139 
cytometry as previously described (35, 36), using re-stimulation with 2 µg/mL S291 MERS-CoV S-specific 140 
peptide (VYDTIKYYSIIPHSI); for vaccine cellular immunogenicity (37)); or 1 µg/mL E3 and F2(G) MVA 141 
vector-specific peptides (38) (for anti-MVA immune responses). In the absence of peptide re-142 
stimulation, the frequency of IFN-ɶ+ cells, which was typically 0.1% by flow cytometry or less than 50 SFC 143 
by ELISpot, was subtracted from tested re-stimulated samples. 144 
ELISA 145 
 ?ʅŐ/ml with capturing antigen (S1 recombinant protein from MyBioSource, CA, USA) were used to coat 146 
ELISA plates, and standard endpoint ELISA protocol was followed, as previously described (39). Sera 147 
were prepared in a 10-fold serial dilution in W^ ?dĂŶĚƚŚĞŶ ? ?ʅůǁĞƌĞƉůĂƚĞĚŝŶĚƵƉůŝĐĂƚĞǁĞůůƐ ?^ĞƌƵŵ148 
from a naïve BALB/c mouse was included as a negative control. Goat anti-mouse total IgG conjugated to 149 
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alkaline phosphatase (Sigma) and PNPP tablet (20 mg p-nitrophenylphosphate, SIGMA) substrate were 150 
used in the assay. 151 
MERSpp Neutralisation assay 152 
MERS pseudotyped viral particles (MERSpp) were produced and titrated using Huh7.5 cell line as 153 
described previously (40). For the MERSpp neutralization assay, serum samples were serially diluted in 154 
96-well white plates (Nunc). A standard concentration of the MERSpp were added to the wells and 155 
plates were incubated for 1 h at 37 °C. After incubation, Huh7.5 cells (10,000 cells per well) were added 156 
to the plate in duplicates. Following 48 h incubation, cells were lysed and luciferase activity was 157 
measured. IC90 neutralisation titres were calculated for each mouse serum sample using GraphPad 158 
Prism.  159 
Virus neutralisation assay 160 
Induction of virus-neutralising antibodies was confirmed according to previously published protocols 161 
(37, 41). Briefly, mouse serum samples were tested for their capacity to neutralise MERS-CoV (EMC 162 
isolate) infections in vitro with 100 50% tissue culture infective doses (TCID50) in Huh-7 cells. Sera of non-163 
immunised mice served as negative control.  164 
Statistical analysis  165 
GraphPad Prism (GraphPad software) was used for statistical analysis and to plot data. 166 
Ethics statement 167 
All animal procedures were performed in accordance with the terms of the UK Animals (Scientific 168 
Procedures) Act (ASPA) for the project licenses 30/2414 or 30/2889 and were approved by the 169 
University of Oxford Animal Care and Ethical Review Committee. All mice were housed for at least 7 170 
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days for settlement prior to any procedure in the University animal facility, Oxford, UK under Specific 171 
Pathogen Free (SPF) conditions. 172 
Results 173 
Construction and antigen expression of MERS-CoV vaccine candidates 174 
The spike gene from a camel isolate (Camel/Qatar_2_2014 MERS-CoV isolate, GenBank accession 175 
number KJ650098.1) was cloned into four shuttle vectors that facilitate homologous recombination with 176 
the genome of ChAdOx1 or MVA. Four recombinant viral vectors, two ChAdOx1 and two MVA, were 177 
derived as described in the materials and methods. ChAdOx1 based vaccine candidates were generated 178 
with or without the signal peptide of the human tissue plasminogen activator gene (tPA). The spike 179 
transgene expression in ChAdOx1 MERS vaccine candidates is under the control of the human 180 
cytomegalovirus major immediate early promoter (CMV IE) that includes intron A. In MVA MERS vaccine 181 
candidates, the tPA was also inserted upstream of the spike transgene, which was under the control of 182 
either the ectopic mH5 promoter or the endogenous F11 promoter (Figure 1A). All of our MERS-CoV 183 
vaccine candidates contain the same codon-optimized spike transgene.The expression of the newly 184 
synthesized transgene was first tested by transfection of an African green monkey kidney cell line (Vero 185 
cells) with the adenovirus shuttle vector, and immunofluorescence staining of the transfected cells 186 
(Figure 1B and 1C). This was performed to confirm the expression of the codon optimized spike 187 
transgene in mammalian cells. The level of transgene expression from the four vaccine candidates was 188 
not evaluated in vitro. We have previously reported that differences in MVA promoter activity 189 
detectable in vitro does not correlate with in vivo immunogenicity (31), and that only in vivo expression 190 
correlates with the in vivo immunogenicity. 191 
Humoral Immunogenicity of ChAdOx1 based MERS-CoV vaccine candidates 192 
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To evaluate humoral immune responses to ChAdOx1 MERS with or without tPA, BALB/c mice were 193 
vaccinated with 1x10
8
 IU of ChAdOx1 intramuscularly. Serum samples from 14 and 28 d.p.i. were 194 
collected and evaluated by ELISA. Both vaccine candidates induced a high level of S1-specific antibodies 195 
(mean endpoint titre (Log10) = 4.8  with tPA, 4.7 without tPA) , unlike the control vaccine, ChAdOx1 196 
encoding enhanced green fluorescent protein (ChAdOx1-eGFP, mean endpoint titre (Log10) = 1). These 197 
antibody levels were similar between the two candidates (with or without tPA) at day 14. However, at 198 
28 d.p.i. ChAdOx1 MERS with tPA induced significantly higher S1-specific antibodies than ChAdOx1 199 
MERS without tPA (mean endpoint titre (Log10) = 5.13 with tPA, 4.6 without tPA,  Figure 2A).  Serum 200 
samples from day 28 were selected for MERSpp neutralisation assay. Serum antibodies induced by 201 
ChAdOx1 MERS with tPA showed significantly higher neutralisation activity than without tPA (mean titre 202 
IC90 (Log10) =  2.8 with tPA, 2.2 without tPA; Figure 2B).  In order to confirm that the psuedotyped virus 203 
neutralisation assay was producing biologically relevant results, serum samples from mice immunised 204 
with ChAdOx1 MERS with tPA were also tested in a neutralisation assay utilising wildtype MERS virus. 205 
This assay confirmed the neutralisation activity of mouse antibodies (nAb) with a median of 360 VNT 206 
(Virus Neutralization Test antibody titre; Figure 2C). We therefore continued to evaluate ChAdOx1 MERS 207 
with tPA in addition to generating MVA MERS vaccine candidates with tPA. 208 
Cellular Immunogenicity of ChAdOx1 based MERS-CoV vaccine candidates 209 
Having established the utility of tPA in ChAdOx1 MERS vaccines (referred to as ChAdOx1 MERS in the 210 
rest of this report) at increasing humoral responses, spleens were collected at 28 d.p.i. from immunised 211 
BALB/c mice. Splenocytes were processed to evaluate cellular immune responses to ChAdOx1 MERS in 212 
ELISpot and Intracellular cytokine staining (ICS). Peptide S291, described by others (37), was used to re-213 
stimulate the cells in both assays and ELISpot data showed a high level of IFN-ɶ secreting splenocytes 214 
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(Median = 1300 SFU/10
6
 splenocytes; Figure 3A). ICS data confirmed the IFN-ɶ secreting CD8+ 215 
splenocytes also secreted TNF-ɲ and IL-17 (Figure 3B).  216 
Immunogenicity of Heterologous ChAdOx1 and MVA vaccination against MERS-CoV 217 
To evaluate humoral immune responses to heterologous prime-boost vaccination, BALB/c mice were 218 
immunised with ChAdOx1 MERS vaccine and boosted with one of two different MVA MERS vaccine 219 
candidates four weeks later. The MVA based candidates differ in the promoters that controls the 220 
transgene expression:  F11-MVA MERS utilises the endogenous strong early F11 promoter and mH5-221 
MVA MERS utilises the ectopic early/late mH5 promoter. Serum samples from 28 d.p.i. (post-prime) or 222 
42 d.p.i. (post-boost) were collected and evaluated by ELISA and MERSpp neutralisation assay. At 28 223 
d.p.i. ChAdOx1 MERS induced similar levels of S1-specific antibodies and nAb as observed previously 224 
(Figure 4A and B). At 42 d.p.i. S1-specific antibodies were boosted to a higher level (mean endpoint titre 225 
(Log10) = 5 by ChAdOx1 MERS boosted to 5.8 by mH5-MVA MERS or 5.9 by F11-MVA MERS); Figure 4A) 226 
with nAb also enhanced to a statistically significant level (mean titre IC90 (Log10) = 2.87 by ChAdOx1 227 
MERS boosted to 3.3 by mH5-MVA MERS or 3.5 by F11-MVA MERS; Figure 4B). There was no difference 228 
in antibody levels induced using either the F11 or mH5 promoter in the MVA.  229 
At 42 d.p.i. splenocytes were also processed to evaluate cellular immune responses to ChAdOx1 MERS 230 
MVA MERS prime-boost vaccination in ELISpot and ICS as shown in Figure 3. The T cell responses to 231 
MERS S were boosted by the MVA vaccinations; in the ICS experiments, F11-MVA and mH5-MVA 232 
boosted the percentage of IFN-ɶ+ splenic CD8+ T cells to 7.3 and 5.2% respectively (Figure 4D) whereas 233 
the percentage was 2.5% after ChAdOx1 MERS prime in Figure 3B. The percentage of TNF-ɲ+ splenic 234 
CD8
+
 T cells were also increased by MVA boost (comparing Figure 3B and 4D). Utilising the F11 promoter 235 
resulted in a trend towards greater cell-mediated immunogenicity (Figure 4C and D). Splenocytes were 236 
also re-stimulated with MVA backbone-specific E3 and F(G)2 peptides and evaluated in ICS. Both MVA 237 
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based vaccines induced similar responses to E3 or to F(G)2 peptides, 2 weeks after MVA vaccination 238 
(Figure 4E and F). This similarity confirmed the efficiency of vaccine titration, vaccination, and sample 239 
processing because responses to each of those peptides are not expected to be different unless there is 240 
variation in the doses administered or sample preparation. Overall, MVA MERS vaccines were able to 241 
boost the humoral and cellular immune responses to ChAdOx1 MERS prime vaccination. There was no 242 
difference between the F11 and mH5 promoter in the resulting antibody titres after ChAdOx1 243 
prime/MVA boost, but there was a trend towards increased cellular immunogenicity when the F11 244 
promoter was used.  245 
Immunogenicity of Homologous MVA vaccination against MERS-CoV 246 
To evaluate humoral immune responses to a homologous MVA MERS prime-boost vaccination, two 247 
groups of BALB/c mice were immunised with F11-MVA MERS or mH5-MVA MERS and boosted with the 248 
same vaccine after three weeks. Serum samples from 21 d.p.i. (post-prime) or 42 d.p.i. (post-boost) 249 
were collected and evaluated in ELISA and MERSpp neutralisation assays. At 21 d.p.i. F11-MVA MERS 250 
and mH5-MVA induced similar levels of S1-specific antibodies (mean endpoint titre (Log10) = 3.2 and 2.8 251 
respectively; Figure 5A). At 42 d.p.i S1-specific antibody levels had increased to  4.7  and 4.8 respectively 252 
(Figure 5A). The titres of nAb (MERS pp assay) were also similar for both vaccines (mean titre IC90 (Log10) 253 
= 2.71 (F11-MVA MERS) and 2.76 respectively; Figure 5B). Utilising different promoters in MVA vectors 254 
did not result in differences in the induced antibody levels. However, at 42 d.p.i. IFN-ɶ ƐĞĐƌĞƚŝŶŐ255 
splenocytes induced by F11-MVA MERS were statistically significantly higher than those of mH5-MVA 256 
MERS ((Median = 525 and 249 SFU/10
6
 splenocytes, respectively, Figure 5C). Both MVA vaccines induced 257 
similar vector-specific immune responses as expected (Figure 5D and E).   258 
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Discussion 259 
Vaccines against MERS-CoV have been developed and tested in a number of animal models (including 260 
non-human primates (42-44) and camels (45)) as well as in human clinical trials (46). All vaccine 261 
candidates focused on the spike antigen because it contains the receptor-binding domain used for cell 262 
entry by the virus, against which neutralising antibodies may be induced, and it is conserved. Therefore, 263 
the improvement of MERS-CoV vaccines focuses on platform and vaccination regimens rather than 264 
antigen selection and optimisation. Here, we focused on using the same antigen (transgene) to develop 265 
a vaccine against MERS-CoV, and to assess different vectors, different versions of each vector, and 266 
different vaccination regimens. We generated a number of MERS-CoV vaccine candidates based on the 267 
same codon optimized spike transgene and ensured its expression in vitro before we evaluated the 268 
humoral and cellular immunogenicity in a pre-clinical BALB/c mouse model. ChAdOx1 based vaccine 269 
candidates were produced with or without tPA. The tPA signal peptide was predicted to enhance the 270 
humoral immunogenicity of encoded vaccine antigens, based on previous reports (29). Our data 271 
supported this hypothesis and showed a significant increase in the S1-specific antibody levels at 28 d.p.i. 272 
The level of neutralising antibodies was also increased when tPA was utilised. However, ChAdOx1 MERS 273 
without tPA was still a potent vaccine candidate, inducing a high level of both S1-specific binding 274 
antibodies and MERS-CoV neutralising antibodies. Neutralisation activity of mouse serum antibodies 275 
was assayed by using MERS-CoV pseudotyped viral particles (MERSpp), an approach used by a number 276 
of researchers for other human pathogens such as HIV, Influenza, and HCV to overcome the necessity of 277 
handling BSL-3 viruses (40). Additionally, we confirmed the ability of serum samples from vaccinated 278 
mice to neutralise live MERS virus. We therefore selected ChAdOx1 MERS with tPA (simply referred to 279 
ChAdOx1 MERS) for further evaluation.  280 
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ChAdOx1 MERS also induced cellular responses for MERS S, with polyfunctional CD8
+
 T cells detected in 281 
the spleen of immunized mice. This supports the potency of the ChAdOx1 viral vector in inducing T 282 
cellular immunity, observed previously in animal models (26, 32, 47) as well as in humans (33). Following 283 
ChAdOx1 prime/MVA boost, MVA significantly boosted the neutralizing antibody titres to higher levels. 284 
No difference in humoral immunity was found when either the F11 or mH5 promoter was used.  285 
Regarding the promoter effect on MVA cellular immunogenicity, we have previously reported that 286 
utilising the F11 promoter enhanced malaria and influenza antigens in MVA (31). Here, we again report 287 
that F11-MVA MERS induced higher T cell responses than mH5-MVA MERS in a homologous prime-boost 288 
MVA MERS vaccination.  289 
All of our vaccine candidates induced humoral (with nAb) and cellular immune (with polyfunctional CD8
+
 290 
T cell) responses against MERS-CoV spike antigen. Modest effects on immunogenicity of different 291 
versions of the vaccines were noted, with the use of the tPA leader sequence in ChAdOx1, and the use 292 
of the F11 promoter in MVA producing small increases in immunogenicity compared to no leader 293 
sequence, or the mH5 promoter. The protective level of either antibodies or cellular immunity required 294 
to counter MERS-CoV infection in humans or in animal models is not yet defined, despite some efforts 295 
(48-51).  The ideal vaccine would provide rapid onset of immunity and complete protective efficacy after 296 
a single dose, with a long duration of immunity. Complete protective efficacy of one dose of ChAdOx1 297 
expressing the external glycoprotein of Rift Valley Fever Virus has been demonstrated in multiple 298 
species and it is already known that ChAdOx1 RVF is highly immunogenic in camels (32). To date, the 299 
only vaccine against MERS to be tested in camels is an MVA vectored vaccine (41) which was protective 300 
in hDPP4 transgenic mice immunized with a homologous prime/boost regimen (37) but in camels 301 
required two doses given both intranasally and intramuscularly to provide partial protection and 302 
reduction of virus shedding (45). Here we find that a single dose of ChAdOx1 MERS is as immunogenic as 303 
two doses of MVA MERS, suggesting that this regimen should be tested for protective efficacy in camels. 304 
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However if this is not completely protective, administration of MVA MERS as a heterologous boost 305 
should be considered next. In our hands one dose of MVA resulted in an endpoint titre of 3 logs, two 306 
doses of MVA produced 4.7 logs, one dose of ChAdOx1 produced 5 logs, and ChAdOx1/MVA prime 307 
boost produced 5.9 logs.  If a single dose of ChAdOx1 MERs is not protective and a two dose regimen is 308 
required, ChAdOx1/MVA would be more likely to provide complete protection than MVA/MVA. 309 
 ChAdOx1 MERS should now be evaluated for immunogenicity and efficacy in larger animal species, 310 
including both camels and humans.  311 
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Figure legends 312 
Figure 1: Construction of MERS-CoV vaccine candidates 313 
A: schematic representation of ChAdOx1 and MVA based vaccines, each encodes the same MERS-CoV spike gene (MERS-CoV S). 314 
The S gene was inserted into the E1 region of ChAdOx1 genome or into the F11L locus of MVA genome. tPA: Human tissue 315 
plasminogen activator (tPA) signal peptide sequence. IE CMV: The human cytomegalovirus major immediate early promoter. 316 
mH5 and F11: Poxviral promoters. LHA: left homology arm sequence. RHA: right homology arm sequence. B: The expression of 317 
spike transgene, cloned into a plasmid vector, was validated by transfection into an African green monkey kidney cell line (Vero 318 
cells) and confirmed by immunostaining. C: Untransfected cells control. Green colour represents detection of the spike protein. 319 
Blue colour represents nuclei by staining nucleic acid with DAPI. 320 
Figure 2: Antibody responses to ChAdOx1 MERS vaccine candidates. 321 
BALB/c mice (n = 6) were immunised with a single injection of ChAdOx1 MERS that either encodes or lacks tPA signal peptide, 322 
intramuscularly at 1x10^8 IU. A control group of mice were immunised with ChAdOx1 expressing eGFP instead of MERS-CoV S 323 
gene. Serum samples were collected at 14 and 28 days post immunisation (d.p.i.). S1-binding antibodies were detected at both 324 
time points by ELISA (A) and neutralisation activity of the antibodies were confirmed by MERS-CoV pseudotyped viral particles 325 
(MERSpp) neutralisation assay (B) or neutralisation assay (C). Individual data points are shown with line as the median. Data are 326 
representative of two independent experiments. Statistical significance by Kruskal ?Wallis test is shown.  327 
Figure 3: Cellular immune responses to ChAdOx1 MERS vaccine candidate. 328 
BALB/c mice (n = 6) were immunised with a single injection of ChAdOx1 MERS that encodes tPA signal peptide intramuscularly 329 
at 1x10^8 IU. Twenty eight days post-immunisation, IFN-ɶex vivo ELISpot (A) or Intracellular Cytokine Staining (ICS (B)), were 330 
performed to determine the percentage of splenic IFN-ɶsecreting CD4+ and CD8+ after in vitro re-stimulation with a MERS-CoV 331 
S-specific peptide. Individual data points are shown with line as the median (A) or error bars as the SD (B). Data are 332 
representative of two independent experiments. 333 
Figure 4: Humoral and cellular immunogenicity of heterologous ChAdOx1 MERS and MVA MERS 334 
vaccination. 335 
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BALB/c mice (n = 6) were immunised with ChAdOx1 MERS that encodes tPA signal peptide, intramuscularly at 1x10^8 IU. At 28 336 
d.p.i. mice were boosted with MVA MERS at 1x10^6 pfu. MVA MERS candidates either contain mH5 or F11 promoter for 337 
transgene expression. Serum samples were collected at 28 (post-prime) and 42 (post-boost) d.p.i. S1-binding antibodies were 338 
detected at both time points by ELISA (A) and neutralisation activity of serum antibodies at 42 d.p.i. were confirmed by MERSpp 339 
neutralisation assay (B). At 42 d.p.i, IFN-ɶ ex vivo ELISpot (C) or Intracellular Cytokine Staining (ICS (D)) were performed to 340 
determine the percentage of CD8
+ 
IFN-ɶ+ splenocytes after in vitro re-stimulation with a MERS-CoV S-specific peptide. ICS of 341 
splenocytes re-stimulated with MVA-specific peptides (F(G)2 and E3) was also performed (E and F). Individual data points are 342 
shown with line as the median. Data are representative of two independent experiments. Statistical significance by Kruskal ?343 
Wallis test is shown. Symbols are closed squares (ඵ) for ChAdOx1 prime responses, open circles (A?) for mH5-MVA boost 344 
responses, and closed circles (භ) for F11-MVA boost responses. 345 
Figure 5: Humoral and cellular immunogenicity of homologous MVA MERS vaccination. 346 
BALB/c mice (n = 6) were immunised with MVA MERS at 1x10^6 pfu, intramuscularly, in a homologous prime-boost vaccination 347 
with three-weeks interval. MVA MERS candidates either contain mH5 or F11 promoter for transgene expression. Serum 348 
samples were collected at 21 (post-prime) and 42 (post-boost) d.p.i. S1-binding antibodies were detected at both time points by 349 
ELISA (A) and neutralisation activity of serum antibodies at 42 d.p.i. were confirmed by MERSpp neutralisation assay (B). At 42 350 
d.p.i splenocytes were processed and re-stimulated with a MERS-CoV S-specific peptide (CD8
+
 T cell specific) for IFN-ɶex vivo 351 
ELISpot (C). ICS of splenocytes re-stimulated with MVA-specific peptides (F(G)2 and E3) was also performed (D and E) as was 352 
performed in figure 4. Individual data points are shown with line as the median. Data are representative of two independent 353 
experiments. Statistical significance by Kruskal ?Wallis test is shown. Symbols are open circles (A?) for mH5-MVA and closed 354 
circles (භ) for F11-MVA.  355 
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